Clinical trial of treatment of laryngeal cancer by recombinant adenovirus p53 combined with chemotherapy / 临床耳鼻咽喉头颈外科杂志
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
;
(24): 848-850, 2007.
Article
in Chinese
| WPRIM
| ID: wpr-748324
ABSTRACT
OBJECTIVE@#To evaluate the effectiveness of recombinant adenovirus p53 injection (rAd2p53) combined with cisplatin plus 5-fluorouracil regimen in treating laryngeal carcinoma.@*METHOD@#Tumour animal models were established in the back of mice with Hep-2 cell line. Recombinant adenovirus p53 injection (rAd2p53) were transduced to tumor-bearing mouse by direct intratumoral injection combine with cisplatin plus 5-fluorouracil ivgtt. The control group 1 was given recombinant adenovirus p53 injection (rAd2p53) simplex. The control group 2 was administered with cisplatin plus 5-fluorouracil ivgtt simplex. Then compare the diameters of pro-treatment with that of post-treatment and test group with controls.@*RESULT@#Tumor growth was significantly inhibited following combined rAd2p53 gene therapy with cisplatin plus 5-fluorouracil chemotherapy compared to single rAd2p53 gene therapy and cisplatin plus 5-fluorouracil chemotherapy controls.@*CONCLUSION@#Local injection of rAd2p53 combined with cisplatin plus 5-fluorouracil chemotherapy is a promising treatment to laryngeal cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Genetic Therapy
/
Adenoviridae
/
Laryngeal Neoplasms
/
Genes, p53
/
Drug Evaluation, Preclinical
/
Genetic Vectors
/
Genetics
/
Mice, Inbred C3H
/
Neoplasms, Experimental
Limits:
Animals
Language:
Chinese
Journal:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS